pharmaphorum September 19, 2024
Organon is paying $175 million upfront to buy Roivant’s dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis.
If it goes through, the deal will also mark the expansion of Organon’s dermatology business into the US, and accelerate the rollout of Vtama (tapinarof) in international markets, said the two companies.
Along with the upfront payment, Organon is offering a $75 million milestone payment if Vtama gets an FDA green light in atopic dermatitis, along with other payments of up to $950 million if the drug hits its sales targets, taking the total value to around $1.2 billion.
Vtama is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent...
Today's Sponsors
Today's Sponsor